Anzeige
Mehr »
Dienstag, 13.05.2025 - Börsentäglich über 12.000 News
Titan für Raketen, Vanadium für Batterien: Radar-Projekt perfekt für die Industrie-Revolution!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A116Z9 | ISIN: BMG570071099 | Ticker-Symbol: LUP
Frankfurt
12.05.25 | 09:20
0,220 Euro
+0,92 % +0,002
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
LUYE PHARMA GROUP LTD Chart 1 Jahr
5-Tage-Chart
LUYE PHARMA GROUP LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,2200,23612.05.

Aktuelle News zur LUYE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.04.LUYE PHARMA (02186): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 28 MAY 20251
29.04.LUYE PHARMA (02186): NOTICE OF ANNUAL GENERAL MEETING1
29.04.LUYE PHARMA (02186): PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND RE-ELECTION OF RETIRING DIRECTORS INCLUDING INDEPENDENT ...1
29.04.LUYE PHARMA (02186): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 20241
29.04.LUYE PHARMA (02186): ANNUAL REPORT 20241
LUYE PHARMA Aktie jetzt für 0€ handeln
10.04.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT ROTIGOTINE LUYE TRANSDERMAL PATCH LAUNCHED IN THE UNITED KINGDOM1
07.04.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT CLASS 1 INNOVATIVE ANTIDEPRESSANT RUOXINLIN APPROVED FOR MARKETING IN MACAO-
31.03.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH APPROVED FOR MARKETING IN JAPAN1
14.03.LUYE PHARMA (02186): NOTICE OF BOARD MEETING3
14.03.Goldman Sachs lifts Luye Pharma stock rating to neutral4
10.03.LUYE PHARMA (02186): CHANGE OF NON-EXECUTIVE DIRECTOR3
10.03.LUYE PHARMA (02186): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION4
15.01.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED FOR THE PHASE 2 CLINICAL STUDY OF THE GROUP'S NEW DRUG LY03015 IN CHINA8
14.01.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT APPROVAL OBTAINED FOR THE GROUP'S NEW DRUG LY03020 FOR CLINICAL TRIALS IN THE U.S.1
18.12.24LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING IN THE COMPANY BY CONTROLLING SHAREHOLDER3
16.12.24LUYE PHARMA (02186): OVERSEAS REGULATORY ANNOUNCEMENT5
13.12.24LUYE PHARMA (02186): COMPLETION OF THE ISSUE OF US$50,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 20257
03.12.24PHARMA MAR, S.A.: The Company announces that its partner Luye Pharma Group Ltd has received approval for commercialization for Zepzelca® (lurbinectedina) in China.12
03.12.24LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT APPROVAL OF ZEPZELCA (LURBINECTEDIN FOR INJECTION) FOR MARKETING IN MAINLAND CHINA1
28.11.24LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - RUOXINLIN AND OTHER DRUGS INCLUDED ON CHINA'S 2024 NATIONAL REIMBURSEMENT DRUG LIST8
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1